44 results on '"Kallmann B"'
Search Results
2. Long-term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials
3. „Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie
4. Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension
5. „Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie
6. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
7. Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose
8. Monitoring and management of MS patients starting natalizumab therapy in Germany — /INS;Final results of the prospective TYSTART study
9. Cladqol (cladribine tablets - evaluation of quality of life) study : evaluating qol 12 months after treatment initiation with cladribine tablets
10. Injektionshilfen in der Basistherapie der Multiplen Sklerose
11. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis
12. Isolation of Brucella melitensis from a patient with hearing loss
13. Neue Therapieansätze bei Multipler Sklerose
14. Prognostischer Wert von evozierten Potentialen für den Krankheitsverlauf bei der Multiplen Sklerose
15. Unterschiede im Genexpressionsmuster bei schubförmiger und primär progredienter Multipler Sklerose
16. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
17. Cytokine secretion patterns in twins discordant for Type I diabetes
18. Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules
19. Prognostischer Wert von evozierten Potentialen für den Krankheitsverlauf bei der Multiplen Sklerose
20. Unterschiede im Genexpressionsmuster bei schubförmiger und primär progredienter Multipler Sklerose
21. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
22. Pathogenesis and Therapeutic Concepts of Organ-Specific Autoimmune Diseases: Report of an Interdisciplinary Workshop in Würzburg, April 29–30, 1999
23. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease
24. Interleukin-10 is a predominant cytokine in atopic dermatitis
25. Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide
26. Was gibt es Neues in der multiplen Sklerose?
27. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.
28. Injektionshilfen in der Basistherapie der Multiplen Sklerose
29. Neue Therapieansätze bei Multipler Sklerose
30. Exogenous nitric oxide modulates cytokine production in human leukocytes
31. Therapy and management of relapsing-remitting multiple sclerosis,Therapieziele und Therapie - management bei schubförmigremittierender Multipler Sklerose
32. Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity (FEB 11761)
33. Human cerebral endothelial cells are a potential source for bioactive BDNF
34. Inflammation in multiple sclerosis: the good, the bad, and the complex
35. REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program.
36. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
37. [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].
38. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
39. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
40. An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM).
41. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
42. Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
43. Inflammation in multiple sclerosis: the good, the bad, and the complex.
44. UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.